Search Results 1061-1070 of 11270 for Antifungal Resistance

1. Dr. Catherine Rasberry Archives - Mayo Clinic News Network

   infectious diseases specialist at Mayo Clinic, discusses the growing problem of antibiotic resistance. And Dr. Catherine Rasberry, a health scientist in the ...

2. Arthritis - Doctors and departments - Mayo Clinic

   Learn about how different types of arthritis affect joints in different ways, along with how to get relief from arthritis pain.

3. Dupilumab Treatment on Sinonasal Respiratory Symptoms and Sense of Smell in Ethnically Diverse Patients with Chronic Rhinosinusitis and Nasal Polyps - Mayo Clinic

   Suspected or diagnosed allergic fungal rhinosinusitis. Suspected or diagnosed cystic fibrosis. Dupixent coverage denied through insurance or Dupixent MyWay ...

5. A Study To Evaluate Testing The Addition Of Targeted Radiation Therapy To Surgery And The Usual Chemotherapy Treatment For Stage I-IIIA Malignant Pleural Mesothelioma - Mayo Clinic

   antibiotics, antiviral, or antifungal treatments. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the ...

6. Medical Research & Education - Mayo Clinic News Network

   ... resistant microbes, Mayo. Individualized Medicine. Science Saturday ... resistant microbes, Mayo Clinic research shows. Susan Murphy. April 2, 2022.

7. A Study To Test The Combination Of Cabozantinib, Nivolumab, And Ipilimumab (CaboNivoIpi) For Advanced Differentiated Thyroid Cancer - Mayo Clinic

   Patients must have radioactive iodine (RAI)-refractory/resistant disease as defined by one or more of the following criteria: One or more measurable lesions ...

8. Anne Gingery, Ph.D. - Mayo Clinic Faculty Profiles

   Mayo Clinic's Anne Gingery, Ph.D., focuses on studying the impacts of aging, cellular senescence, immune dysregulation and metabolic dysfunction in ...

9. Study Treating Patients With Relapsed Or Refractory Aggressive B-cell Lymphomas Using Nivolumab With Or Without Varlilumab - Mayo Clinic

   Monoclonal antibodies, such as varlilumab and nivolumab, may work by stimulating the immune system to attack cancer tumor cells. Participation eligibility.

10. A Study To Evaluate The Effectiveness, Safety And Tolerability Of PF-06823859 In Adults With Moderate-to-Severe Dermatomyositis - Mayo Clinic

    The purpose of this study is to evaluate the investigational drug PF-06823859 and a placebo administered to adult pPatients with moderate-to- severe ...